Multiple analyses confirm the association of serum 25(OH)D concentration with Breslow thickness of primary melanomas.

<p>Additional statistical tests, including gender and time of blood draw in multiple analyses, confirmed our finding that serum 25(OH)D concentrations are associated with Breslow thickness of primary melanomas (n = 307; 17 Patients were excluded from this cohort due to missing clinical data). Considering Breslow thickness of primary melanomas as dependent and gender, season of blood draw as well as serum 25(OH)D concentration as independent variables, the adjusted serum 25(OH)D concentration effect resulted in a p-value of 0.013.</p><p>Multiple analyses confirm the association of serum 25(OH)D concentration with Breslow thickness of primary melanomas.</p

Serum 25(OH)D concentrations are associated with Breslow thickness of primary melanomas.

<p>Median Breslow thickness (black horizontal line) in melanoma patients is shown (1a) (<10 ng/ml = 1.9 mm, n = 77; 10–20 ng/ml = 1.4 mm, n = 122; >20 ng/ml = 1 mm, n = 108; total n = 307; p = 0.002). 17 Patients were excluded from this cohort due to missing clinical data. Boxes represent the values within the 25th and 75th percentiles (1a). We report evidence of an inverse J-shaped curve (p = 0.033), indicating that high serum 25(OH)D concentrations (>40 ng/ml) may be associated with thicker primary melanomas as well. Median Breslow thickness and 25(OH)D serum concentration at time of diagnosis from melanoma patients is shown (<10 ng/ml = 1.9 mm [ci 95%: 1.3–2.5], n = 77; 10–20 ng/ml = 1.4 mm [ci 95%: 1.1–1.8], n = 122; 20–30 ng/ml = 1.00 mm [ci 95%: 0.73–1.5], n = 65; 30–40 ng/ml = 0.8 mm [ci 95%: 0.4–1.85], n = 31; 40–50 ng/ml = 1.155 mm [ci 95%: 0.65–2.7], n = 8; >50 ng/ml = 1.25 mm [ci 95%: 0.5–2.0], n = 4; total n = 307; p = 0.033). 17 Patients were excluded from the cohort due to missing clinical data (1b).</p

Please note lower serum 25(OH)D concentrations in melanoma patients (diagnosed in wintertime) as compared to controls, and in metastasized as compared to non-metastasized patients.

<p>In the cohort of all melanoma patients significant (p = 0.003) age-related differences in serum 25(OH)D concentrations were observed (20–51 yrs.: median = 18.5 ng/ml, n = 105; 52–66 yrs.: median = 16.4 ng/ml, n = 108; >67 yrs.: median = 14.2 ng/ml, n = 111).</p><p>Please note lower serum 25(OH)D concentrations in melanoma patients (diagnosed in wintertime) as compared to controls, and in metastasized as compared to non-metastasized patients.</p

25(OH)D concentration, age, season and Breslow thickness of primary melanomas.

<p>We found significant (p<0.001) variations in serum 25(OH)D concentrations throughout the seasons in melanoma patients (n = 324), with a peak in autumn (Aug-Oct) (median = 21.3 ng/ml) and a low in springtime (Feb-Apr) (median = 10.15 ng/ml) (2a). An association of Breslow thickness and season was not observed (p = 0·543, n = 307), 17 patients from the cohort were excluded due to missing clinical data (2b). Additionally, we found (p = 0.07) age-related differences in Breslow thickness of primary melanomas (20–51 yrs.: median = 1.1 mm; 52–66 yrs.: median = 1.2 mm; >67 yrs.: median = 1.8 mm) (2c). Boxes represent the values (median) within the 25^th and 75^th percentiles.</p

Multiple analyses confirm that median serum 25(OH)D concentrations are significantly lower in melanoma patients as compared to controls.

<p>Additional statistical tests, including age and time of blood draw (BMI data were not available) in multiple analyses and ANOVA, confirmed that median serum 25(OH)D concentrations are significantly lower in melanoma patients as compared to controls. Considering 25(OH)D as dependent and sex, age, season of blood draw as well as group as independent variables, the adjusted group effect resulted in a p-value of 0,012.</p><p>Multiple analyses confirm that median serum 25(OH)D concentrations are significantly lower in melanoma patients as compared to controls.</p

Serum 25(OH)D concentrations are associated with survival of melanoma patients.

<p>When dividing the cohort of melanoma patients according to their serum 25(OH)D concentrations into quartiles, a significant difference in survival from time of diagnosis between the 1^st (lowest serum 25(OH)D concentrations; 4–9.86 ng/ml) and 4^th (highest serum 25(OH)D concentrations; 24.4–59.6 ng/ml) quartiles is found (p = 0.049). Kaplan-Meier analysis shows a median OS of melanoma patients in the 1^st quartile (n = 81) of 80 months, while in contrast patients in the 4^th quartile (n = 81) have a median OS of 195 months. Age at time of venipuncture has no significant influence on OS (p = 0.2). Tumor stage has a significant influence on OS with p-values<10⁻³ and 0.002 for tumor stages 4 and 3, respectively. This finding may be due to a dependence of tumor stage on 25(OH)D level (3a). Comparing the survival of melanoma patients venipunctured in winter (Nov-Jan) (n = 57) and summer (May-Jul) (n = 92) with each other, no significant difference is observed. The median survival in the winter cohort is 62 months as compared to 57 months in the summer cohort (n = 149; p = 0.056) (3b). The female gender (195 month, n = 150) has a significant longer OS compared to the male gender (141 month, n = 174) (p = 0.003) (3c).</p

ELR CXC chemokine expression in benign and malignant colorectal conditions-7

< 0.05, ** < 0.001, = 30 (CRA), 48 (CRC) and 16 (CRLM), respectively. Fold increase above 1 indicates CXCR2 overexpression in CRA, CRC and CRLM tissues related to unaffected neighbor tissues, respectively.<p><b>Copyright information:</b></p><p>Taken from "ELR+ CXC chemokine expression in benign and malignant colorectal conditions"</p><p>http://www.biomedcentral.com/1471-2407/8/178</p><p>BMC Cancer 2008;8():178-178.</p><p>Published online 25 Jun 2008</p><p>PMCID:PMC2459188.</p><p></p

ELR CXC chemokine expression in benign and malignant colorectal conditions-0

< 0.05, ** < 0.001, = 30 and 48, respectively. Fold increase above 1 indicates chemokine overexpression in CRA and CRC tissues related to unaffected neighbor tissues, respectively.<p><b>Copyright information:</b></p><p>Taken from "ELR+ CXC chemokine expression in benign and malignant colorectal conditions"</p><p>http://www.biomedcentral.com/1471-2407/8/178</p><p>BMC Cancer 2008;8():178-178.</p><p>Published online 25 Jun 2008</p><p>PMCID:PMC2459188.</p><p></p

Univariate analysis of risk factors associated with MRSA carriership upon admission and conditional logistic regression (only significant risk factors depicted in the table).

<p>Risk factors are listed according to OR values of univariate analysis. For detailed description of the risk factors ascertained, please refer to Methods.</p>*<p> = P<0.05.</p

ELR CXC chemokine expression in benign and malignant colorectal conditions-6

Ues of CRA, (B) very weak immunostaining in CRA specimens, (C) weak insular epithelial signals in tumor neighbor tissues of CRC, (D) intense basal and apical epithelial signals and interspersed rare mesenchymal signals in CRC tissues, (E) no substantial reactivity in corresponding neighbour tissues of CRLM and (F) intensive staining signals in epithelial and mesenchymal cells within tumor areas of CRLM specimens (original magnification 200 and 400 fold, respectively).<p><b>Copyright information:</b></p><p>Taken from "ELR+ CXC chemokine expression in benign and malignant colorectal conditions"</p><p>http://www.biomedcentral.com/1471-2407/8/178</p><p>BMC Cancer 2008;8():178-178.</p><p>Published online 25 Jun 2008</p><p>PMCID:PMC2459188.</p><p></p